London, UK, 26 September 2007: Onyvax Ltd, the biotechnology company developing novel cancer therapies, announced today that a Phase IIb clinical trial with Onyvax-P, designed to stimulate the immune system to fight prostate cancer, is now underway at the National Cancer Institute, Bethesda, Maryland.
